急性缺血性脑卒中超早期阿替普酶静脉溶栓155例临床研究

被引：16

作者：

王蕾

姜帅

何柳

方升

徐广会

朱曦

龚蕉椒

杨珊珊

张仲

机构：

[1] 四川省成都市第三人民医院·西南交通大学附属医院

来源：

中国药业 | 2017年 / 26卷 / 21期

关键词：

阿替普酶; 溶栓治疗; 急性缺血性脑卒中; 预后;

D O I：

暂无

中图分类号：

R743.3 [急性脑血管疾病（中风）];

学科分类号：

摘要：

目的观察急性缺血性脑卒中发病4.5 h内重组组织型纤溶酶原激活剂(阿替普酶)静脉溶栓的疗效和安全性,分析影响预后的相关因素。方法选取2014年7月至2016年8月来医院就诊的发病4.5 h内的急性缺血性脑卒中患者234例,分为溶栓组和对照组。其中溶栓组155例静脉予阿替普酶溶栓,对照组79例不进行溶栓治疗。比较两组治疗后的美国国立卫生研究院卒中量表(NIHSS)评分、改良Rankin(mRS)评分,以及脑出血转化和死亡率。结果溶栓组与对照组在治疗后90 d mRS评分差异有统计学意义(P<0.05);两组脑出血、死亡率比较,差异无统计学意义(P>0.05);溶栓治疗后90 d mRS评分的多因素Logistic回归分析结果显示,溶栓是保护因素,服用抗凝药、入院时mRS评分高和入院时NIHSS评分高是预后差的危险因素。结论急性缺血性脑卒中4.5 h内阿替普酶静脉溶栓能降低残疾率,不增加脑出血和死亡风险。服用抗凝药、入院时mRS评分高和入院时NIHSS评分高是预后差的危险因素。

引用

页码：35 / 38

页数：4

共 9 条

[1] Changes in European Label and Guideline Adherence After Updated Recommendations for Stroke Thrombolysis: Results From the Safe Implementation of Treatments in Stroke Registry.[J].Nadim Anani;Michael V. Mazya;Olivier Bill;Rong Chen;Sabine Koch;Niaz Ahmed;Nils Wahlgren;Tiago Prazeres Moreira.Circulation: Cardiovascular Quality and Outcomes.2015, 6_su
[2] Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials
Emberson, Jonathan
Lees, Kennedy R.
Lyden, Patrick
Blackwell, Lisa
Albers, Gregory
Bluhmki, Erich
Brott, Thomas
Cohen, Geoff
Davis, Stephen
Donnan, Geoffrey
Grotta, James
Howard, George
Kaste, Markku
Koga, Masatoshi
von Kummer, Ruediger
Lansberg, Maarten
Lindley, Richard I.
Murray, Gordon
Olivot, Jean Marc
Parsons, Mark
Tilley, Barbara
Toni, Danilo
Toyoda, Kazunori
Wahlgren, Nils
Wardlaw, Joanna
Whiteley, William
del Zoppo, Gregory J.
Baigent, Colin
Sandercock, Peter
Hacke, Werner
[J]. LANCET, 2014, 384 (9958) : 1929 - 1935
[3] Outcome of patients with atrial fibrillation after intravenous thrombolysis for cerebral ischaemia
Padjen, Visnja
Bodenant, Marie
Jovanovic, Dejana R.
Ponchelle-Dequatre, Nelly
Novakovic, Novak
Cordonnier, Charlotte
Beslac-Bumbasirevic, Ljiljana
Leys, Didier
[J]. JOURNAL OF NEUROLOGY, 2013, 260 (12) : 3049 - 3054
[4] The complexities of acute stroke decision-making A survey of neurologists
Shamy, Michel C. F.
Jaigobin, Cheryl S.
[J]. NEUROLOGY, 2013, 81 (13) : 1130 - 1133
[5] Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis
Wardlaw, Joanna M.
Murray, Veronica
Berge, Eivind
del Zoppo, Gregory
Sandercock, Peter
Lindley, Richard L.
Cohen, Geoff
[J]. LANCET, 2012, 379 (9834) : 2364 - 2372
[6] Evolution of the Thrombolytic Treatment Window for Acute Ischemic Stroke
Stemer, Andrew
Lyden, Patrick
[J]. CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2010, 10 (01) : 29 - 33
[7] Safety and efficacy of alteplase in the treatment of acute ischemic stroke.[J].Giuseppe Micieli.Vascular Health and Risk Management.2009, defa
[8] Predictive variables for mortality after acute ischemic stroke
Carter, Angela M.
Catto, Andrew J.
Mansfield, Michael W.
Bamford, John M.
Grant, Peter J.
[J]. STROKE, 2007, 38 (06) : 1873 - 1880
[9] Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials
Hacke, W
Donnan, G
Fieschi, C
Kaste, M
von Kummer, R
Broderick, JP
Brott, T
Frankel, M
Grotta, JC
Haley, EC
Kwiatkowski, T
Levine, SR
Lewandowski, C
Lu, M
Lyden, P
Marler, JR
Patel, S
Tilley, BC
Albers, G
Brott, T
Grotta, J
Bluhmki, PE
Wilhelm, M
Hamilton, S
[J]. LANCET, 2004, 363 (9411) : 768 - 774

← 1 →